


# PRODUCT INFORMATION



## BayCysLT<sub>2</sub> Item No. 10532

**CAS Registry No.:** 712313-33-2  
**Formal Name:** 3-[[[(3-carboxycyclohexyl)amino]carbonyl]-4-[3-[4-(4-phenoxybutoxy)phenyl]propoxy]-benzoic acid  
**Synonym:** CAY10633  
**MF:** C<sub>34</sub>H<sub>39</sub>NO<sub>8</sub>  
**FW:** 589.7  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 220 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

BayCysLT<sub>2</sub> is supplied as a crystalline solid. A stock solution may be made by dissolving the BayCysLT<sub>2</sub> in the solvent of choice, which should be purged with an inert gas. BayCysLT<sub>2</sub> is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of BayCysLT<sub>2</sub> in these solvents is approximately 20 mg/ml.

BayCysLT<sub>2</sub> is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BayCysLT<sub>2</sub> should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BayCysLT<sub>2</sub> has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

BayCysLT<sub>2</sub> is a cysteinyl leukotriene 2 (CysLT<sub>2</sub>) receptor antagonist (IC<sub>50</sub> = 53 nM).<sup>1</sup> It selectively inhibits calcium mobilization induced by leukotriene D<sub>4</sub> (LTD<sub>4</sub>; Item No. 20310) in HEK293 cells expressing human CysLT<sub>2</sub> receptors over HEK293 cells expressing CysLT<sub>1</sub> receptors when used at a concentration of 100 nM. BayCysLT<sub>2</sub> reverses LTC<sub>4</sub>-induced increases in coronary artery perfusion pressure and decreases in contractility in isolated perfused guinea pig hearts.<sup>2</sup> *In vivo*, BayCysLT<sub>2</sub> (3 mg/kg) reduces infarct volume in a human CysLT<sub>2</sub> receptor transgenic mouse model of myocardial ischemia and reperfusion injury induced by left anterior descending coronary artery (LAD) ligation.<sup>1</sup>

### References

1. Ni, N.C., Yan, D., Ballantyne, L.L., *et al.* A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. *J. Pharmacol. Exp. Ther.* **339**(3), 768-778 (2011).
2. Harter, M., Erguden, J., Wunder, F., *et al.* Isophtalic acid derivatives. *Bayer Pharma AG.* **US20060154912A1**, (2006).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/27/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM